Travis Murdoch, HI-Bio CEO

ARCH-backed HI-Bio touts ear­ly da­ta from two tri­als for rare kid­ney dis­ease

A kid­ney-spe­cif­ic au­toim­mune dis­ease with no ap­proved ther­a­pies could face an op­po­nent in felzartam­ab, an in­ves­ti­ga­tion­al mon­o­clon­al an­ti­body, ac­cord­ing to its de­vel­op­er.

Da­ta from two ear­ly tri­als of the an­ti­body were re­leased to­day from Hu­man Im­munol­o­gy Bio­sciences (HI-Bio), which the com­pa­ny says shows pos­i­tive im­pact on pri­ma­ry mem­bra­nous nephropa­thy (PMN), a rare im­mune-me­di­at­ed dis­ease that im­pacts more than 36,000 peo­ple in the US.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.